MELVILLE, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (Nasdaq:BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announced the successful completion of manufacturing for its BRTX-100 Phase 2 clinical trial, marking a key milestone in the development of its lead cell therapy candidate and underscoring the strength of the Company's vertically integrated regenerative medicine platform.
Manufacturing of the BRTX-100 clinical supply was completed in the Company's cGMP ISO-7 certified facility, supporting ongoing clinical development for the treatment of chronic lumbar disc disease.
"This milestone reflects more than operational execution — it highlights the strategic advantage of our integrated manufacturing and biologics platform," said Lance Alstodt, Chief Executive Officer of BioRestorative. "We have built internal capabilities spanning cell sourcing, processing, formulation, and manufacturing, allowing us to control quality, consistency, and scalability across both our therapeutic and commercial programs."
BioRestorative's platform leverages a common biological foundation across multiple applications, including:
BRTX-100, a clinical-stage cell therapy targeting structural disc repair
BioCosmeceuticals, a commercial regenerative biologics platform utilizing secretome-derived components such as exosomes, growth factors, and cytokines
This shared infrastructure enables the Company to translate its cell-based technologies into both therapeutic candidates and commercially available biologic products.
"Our ability to control the full manufacturing lifecycle — from cell processing through final formulation — is a key differentiator," said Suranga Suraweera, Director of Quality & Compliance. "This ensures traceability, reproducibility, and high biological integrity across all of our products, whether for clinical use or commercial applications."
The Company believes this approach provides several strategic advantages:
Consistent, high-quality biologic production across multiple product formats
Scalable manufacturing infrastructure supporting both clinical development and commercialization
Proprietary process and formulation expertise, contributing to product differentiation and potential intellectual property protection
Dual-path value creation, combining near-term commercial opportunities with long-term clinical development
Completion of manufacturing positions BRTX-100 for continued clinical execution, while reinforcing the Company's broader strategy of advancing regenerative biologics across both therapeutic and aesthetic markets. It also contributes to reduced manufacturing-related expense, translating into improved operating costs and margin.